Beacon Biosignals has raised $97m to advance development of its electroencephalogram (EEG) recording technology in areas including precision medicine and diagnostics.
The company’s Series B extension has added new entities to its investor pool, including Samsung Next and JSL Health, upsizing the round from $86m, as previously announced in November 2025.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Bringing Beacon’s cumulative funding to date to over $132m, the initial Series B tranche was led by investors including Google Ventures, Catalio Capital Management, and General Catalyst.
Beacon’s lead product, Waveband, is a headband worn by users while they sleep. Featuring six dry electrodes, the system captures EEG signals that are subsequently analysed using Beacon’s artificial intelligence (AI) technology to aid in the diagnosis of sleep disorders such as narcolepsy.
Broadly, the headband is designed to bring precision neuroscience to clinical trials, helping to speed up drug development. According to Beacon, the company’s application of AI to analyse the neural data Waveband captures, also provides clinicians and biopharma partners with objective measures of brain function that are intended to advance capabilities surrounding research, the improvement of diagnostics, and in guiding new treatments for neurological disorders such as epilepsy and depression.
Several big pharma companies use the technology in some capacity, including Bristol Myers Squibb (BMS), Novartis, and Takeda. In November 2025, Beacon and Takeda expanded a partnership they forged in 2024 that centred on at-home sleep monitoring for trials related to sleep disorders. Under the expanded partnership, the companies are using Beacon’s technology to expedite sleep biomarkers and pattern development with the overall aim to support new diagnostic approaches and close care gaps for individuals with narcolepsy.
Commenting on the Series B round, Beacon’s CEO, Jacob Donoghue commented: “This milestone reflects strong momentum behind our vision to make brain health measurable, scalable, and actionable.”
According to GlobalData analysis, the patient monitoring market, of which EEG data collection is a part, is growing at a CAGR of 1.8% and is forecast to reach a valuation of around $25.9bn in 2035, up from around $21.4bn in 2025.
EEG monitoring systems have a broad range of applications across various conditions, with their prevalence advancing due to their potential in providing diagnostic information that is actionable.
Australia’s Epiminder received Food and Drug Administration (FDA) authorisation in April 2025 for its implantable continuous EEG monitoring system, Minder, that is designed for individuals with epilepsy. As the first implantable EEG monitor approved by the FDA, Epiminder highlighted that long-term EEG data can be analysed more acutely in epilepsy patients by helping clinicians to gain insights into patterns and occurrences that exacerbate an individual’s epilepsy.
